Evidence map›Paper›PMID 40195555›Full record

ArticleCommunications biology2025

A structural and mechanistic model for BSEP dysfunction in PFIC2 cholestatic disease.

Clémence Gruget, Bharat G Reddy, Jonathan M Moore

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Bile acid signaling in health and disease.Molecular biomedicine · 2026
    Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Clémence GrugetMassachusetts Institute of Technology, Cambridge, MA, USA.
Bharat G ReddyRectify Pharmaceuticals, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3131-7433
Jonathan M MooreMassachusetts Institute of Technology, Cambridge, MA, USA. moore@rectifypharma.com.ORCID http://orcid.org/0000-0001-8633-3313

Funding

Establishing a mechanistic foundation for drug discovery: The ABCA4 transporter in Stargardt Disease and other retinopathiesR41EY030401 · NEI · RECTIFY PHARMACEUTICALS, LLC · PI MOORE, JONATHAN · 2019 to 2019
$231k
NEI NIH HHS R41 EY030401
6 · The paper itself

Abstract

BSEP (ABCB11) transports bile salts across the canalicular membrane of hepatocytes, where they are incorporated into bile. Biallelic mutations in BSEP can cause Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC2), a rare pediatric disease characterized by hepatic bile acid accumulation leading to hepatotoxicity and, ultimately, liver failure. The most frequently occurring PFIC2 disease-causing mutations are missense mutations, which often display a phenotype with decreased protein expression and impaired maturation and trafficking to the canalicular membrane. To characterize the mutational effects on protein thermodynamic stability, we carried out biophysical characterization of 13 distinct PFIC2-associated variants using in-cell thermal shift (CETSA) measurements. These experiments reveal a cluster of residues localized to the NBD2-ICL2 interface, which exhibit severe destabilization relative to wild-type BSEP. A high-resolution (2.8 Å) cryo-EM structure provides a framework for rationalizing the CETSA results, revealing a novel, NBD2-localized mechanism through which the most severe missense patient mutations drive cholestatic disease. These findings suggest potential strategies for identifying mechanism-based small molecule correctors to address BSEP trafficking defects and advance novel therapies for PFIC2 and other cholestatic diseases.

Indexed as

ATP Binding Cassette Transporter, Subfamily B, Member 11Cholestasis, IntrahepaticBile Acids and SaltsCryoelectron MicroscopyHumansModels, MolecularMutationMutation, MissenseABCB11 protein, humanATP Binding Cassette Transporter, Subfamily B, Member 11Bile Acids and Salts

Identifiers

PMID40195555
PMCPMC11977275

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.